Redefining Obesity Treatment Through Metabolic Science

We develop first-in-class therapies that activate the body’s own energy-burning pathways, delivering innovative, personalized solutions to improve health and quality of life.

About us

Eolo Pharma is a clinical-stage biotechnology company pioneering new approaches to treat obesity and metabolic disease. By targeting the body’s energy expenditure pathways, we aim to develop transformative therapies that go beyond traditional weight-loss mechanisms. Our lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, a novel biological process with the potential to reset metabolic health. Backed by over a decade of research, our work reflects a commitment to advancing science-driven solutions that improve lives worldwide.

Our

Pipeline

Our NCE library is composed of 60 novel molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.

Indications
Program
Drug Candidate
Discovery & chracterization
Phase I
Phase II
Phase III
Obesity T2 Diabetes NASH Hypertension
Oral thermogenic NCE
MVD 1 analog
NCE
ALS Alzheimer's
NF-kB inhibitor & other
Eolo40
MVD-1

Science

At Eolo Pharma, we apply state-of-the-art biomedical research and mechanism-based drug design to develop first-in-class therapies targeting energy balance and metabolic dysfunction. Our work is rooted in unlocking underexplored biological pathways to deliver scientifically validated treatments that improve patient outcomes worldwide.

Our library of novel chemical entities (NCEs) includes a proprietary collection of small molecules designed to address high-burden, non-communicable diseases. Among them, we highlight MVD1, a lead candidate in our pipeline targeting obesity and its associated metabolic disorders.

Dive into

our world

High-quality products are designed to enhance energy and vitality

Discover the essential elements of our brand platform.

Our purpose  & vision

Get to know about our latest research and developments.

NCE library

Stay up to date with Eolo’s latest events 

Read our latest news

For more information or work applications please reach out to us

Get in touch

Research at Eolo

Discover our collection of peer-reviewed publications, unveiling groundbreaking research in various fields. Engage with our insightful works that bridge science and innovation, offering valuable insights into obesity, ALS, and tissue transplantation. Join us in exploring the forefront of knowledge and unlocking new possibilities in healthcare.

Nature Metabolism: A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss

A Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-κB Inhibition.

A novel nitroalkene vitamin E analogue inhibits the NLRP3 inflammasome and protects against inflammation and glucose intolerance triggered by obesity

Electrophilic nitroalkene-tocopherol derivatives: synthesis, physicochemical characterization and evaluation of anti-inflammatory signaling responses

Partners & supporters